Zhejiang Hisoar Pharmaceutical (002099.SZ) portfolio company's innovative drug NWRD06 injection completed the first subject's enrollment in Phase II clinical trial.

Zhejiang Hisoar Pharmaceutical (002099.SZ) announced that the company recently received a "Notice Letter" from its industrial fund manager, Beijing Guoxin Zhongshu Investment Management Co., Ltd. The company learned that Guoxin Haixiang Equity Investment Partnership Enterprise (Limited Partnership) (hereinafter referred to as "Guoxin Haixiang") invested in Nuowei Biotechnology (Wuxi) Co., Ltd. (hereinafter referred to as "Nuowei Biotech") has officially launched the phase II clinical trial of the world's first nucleic acid drug NWRD06 for preventing recurrence of liver cancer after surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, and has completed the enrollment of the first subject and first dosing. NWRD06 injection is currently the world's first therapeutic nucleic acid drug targeting the liver cancer-specific target GPC3 to enter the phase II clinical stage, with an innovative mechanism of activating specific T cell immunity to clear tumor cells. Based on this mechanism, theoretically, its indications can be expanded to the early treatment stage of cancer, potentially challenging liver cirrhosis indications after obtaining approval for postoperative recurrence of liver cancer, with the possibility of expanding biological rationale; similarly, for more severe advanced liver cancer treatment, as an immune therapy, NWRD06 injection may be combined with existing interventional therapies, immune checkpoint inhibitors (such as PD-1 inhibitors) in the future to explore the potential of treating liver cancer. The phase I registration clinical study of NWRD06 injection has been completed at the Cancer Hospital of the Chinese Academy of Medical Sciences. Based on the treatment strategy targeting GPC3, its core value lies in accurately identifying tumor cells and tiny lesions that are inaccessible to surgical treatment, exerting anti-tumor effects without damaging normal tissues. With the smooth initiation of the phase II clinical trial and enrollment of the first subject, NWRD06 injection has taken a solid step towards clinical application, and is expected to provide a safe and non-invasive option for preventing recurrence for postoperative liver cancer patients in the future, improving patient survival and delivering new hope for health.